Subject has received bevacizumab (Avastin).
Receipt of bevacizumab (Avastin) therapy within 4 weeks of scheduled M032 administration; (receipt of bevacizumab [Avastin] greater than 4 weeks of scheduled M032 administration does not exclude patient)
Use of Avastin in the preceding two weeks or planned use in the forthcoming two weeks and VEGF inhibitors within + 30 days of treatment
May have received 1 prior biologic regimen (i.e. avastin) but not within 4 weeks of enrollment
Patients with gliomas who have had prior treatment with bevacizumab (Avastin) are excluded
Avastin use within 30 days prior to surgery.
No prior therapy with Avastin
Prior or concurrent treatment with Avastin (bevacizumab)
Any patients planning to receive Avastin or any other anti-angiogenic drugs
Prior antiangiogenic therapy (e.g., Bevacizumab/Avastin)
Has the subject received Avastin® (bevacizumab) for this recurrence/progression, or within the 4 weeks prior to planned Visit 1?
Have received any prior treatment with bevacizumab (Avastin).
received Avastin
Patients must be scheduled to receive: 1) standard chemotherapy with/without radiation therapy; OR 2) single-agent bevacizumab (Avastin)